FDA aims for quality through regulatory science

The FDA has added flesh to the regulatory science document it issued last fall, outlining its vision of how the science might be used to enhance oversight efforts. In a strategic plan issued yesterday, the agency revealed its focus areas.

The regulator says it will support "innovative analytical approaches to improve manufacturing and quality through active research," both internally and with outside partners. It also will look into understanding the effects of continuous versus batch manufacturing on drug quality. In addition, it will investigate manufacturing technologies to determine how they affect product failure rates. And it plans to evaluate the role of excipients and complex dosage forms on product safety, efficacy and quality.

The agency also plans to dig into two state-of-the-art manufacturing strategies--process analytical technology and quality by design. It hopes to discern their impact on manufacturers' ability to maintain quality consistency.

Other items on its list include developing analytical methods to evaluate product quality and creating tests to detect and identify microbial contamination.

The plan represents the agency's current thinking, according to a spokesperson. "But as scientific and public health needs evolve, we will continue to revisit and refine this plan."

- here's the FDA's release
- see the report (.pdf)

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.